

Financial news for CCXI dated on 2020-06-10: ChemoCentryx Files For Mixed Offering, Size Not Disclosed

Financial news for CCXI dated on 2020-06-03: ChemoCentryx Phase III ADVOCATE Trial Of Avacopan In ANCA-Associated Vasculitis Highlighted In Oral Plenary Presentations At EULAR And ERA-EDTA Congresses

Financial news for CCXI dated on 2020-05-29: The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immuteq Gets R&D Grant

Financial news for CCXI dated on 2020-05-28: Stocks That Hit 52-Week Highs On Thursday

Financial news for CCXI dated on 2020-05-28: The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetrphase Receives Sweetened Offer

Financial news for CCXI dated on 2020-05-27: Benzinga's Top Upgrades, Downgrades For May 27, 2020

Financial news for CCXI dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for CCXI dated on 2020-05-27: Wells Fargo Initiates Coverage On ChemoCentryx with Overweight Rating, Announces Price Target of \$79

Financial news for CCXI dated on 2020-05-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CCXI dated on 2020-05-22: Stocks That Hit 52-Week Highs On Friday

Financial news for CCXI dated on 2020-05-22: The Daily Biotech Pulse: FDA Nod For Aquestive, Tetrphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

Financial news for CCXI dated on 2020-05-21: Stocks That Hit 52-Week Highs On Thursday

Financial news for CCXI dated on 2020-05-20: The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

Financial news for CCXI dated on 2020-05-19: Canaccord Genuity Maintains Buy on ChemoCentryx, Lowers Price Target to \$58

Financial news for CCXI dated on 2020-05-18: ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)

Financial news for CCXI dated on 2020-05-18: 20 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for CCXI dated on 2020-05-14: JP Morgan Maintains Overweight on ChemoCentryx, Raises Price Target to \$64

Financial news for CCXI dated on 2020-05-13: Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.

Financial news for CCXI dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for CCXI dated on 2020-05-12: Canaccord Genuity Maintains Buy on ChemoCentryx, Raises Price Target to \$68

Financial news for CCXI dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CCXI dated on 2020-05-12: ChemoCentryx shares are trading higher after the company reported Q1 earnings results.

Financial news for CCXI dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for CCXI dated on 2020-05-12: 10 Biggest Price Target Changes For Tuesday

Financial news for CCXI dated on 2020-05-12: Raymond James Reiterates Strong Buy on ChemoCentryx, Raises Price Target to \$102

Financial news for CCXI dated on 2020-05-12: SVB Leerink Reiterates Outperform on ChemoCentryx, Raises Price Target to \$65

Financial news for CCXI dated on 2020-05-11: ChemoCentryx Q1 EPS \$(0.350) Misses \$(0.300) Estimate, Sales \$6.008M Miss \$8.750M Estimate

Financial news for CCXI dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for CCXI dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for CCXI dated on 2020-05-05: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CCXI dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for CCXI dated on 2020-05-04: Stocks That Hit 52-Week Highs On Monday

Financial news for CCXI dated on 2020-05-01: The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO

Financial news for CCXI dated on 2020-04-21: The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives

Financial news for CCXI dated on 2020-03-11: JP Morgan Maintains Overweight on ChemoCentryx, Raises Price Target to \$61

Financial news for CCXI dated on 2020-03-11: Raymond James Maintains Strong Buy on ChemoCentryx, Raises Price Target to \$64

Financial news for CCXI dated on 2020-03-10: ChemoCentryx Q4 EPS \$(0.26), Inline, Sales \$10M Beat \$9.68M Estimate

Financial news for CCXI dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for CCXI dated on 2020-03-08: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Financial news for CCXI dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for CCXI dated on 2020-02-18: JP Morgan Maintains Overweight on ChemoCentryx, Raises Price Target to \$60

Financial news for CCXI dated on 2020-02-14: The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

Financial news for CCXI dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for CCXI dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for CCXI dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CCXI dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for CCXI dated on 2020-02-10: Stocks That Hit 52-Week Highs On Monday

Financial news for CCXI dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for CCXI dated on 2020-02-06: Stocks That Hit 52-Week Highs On Thursday

Financial news for CCXI dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for CCXI dated on 2020-02-05: Stocks That Hit 52-Week Highs On Wednesday

Financial news for CCXI dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for CCXI dated on 2020-02-04: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CCXI dated on 2020-02-04: The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

Financial news for CCXI dated on 2020-02-03: Stocks That Hit 52-Week Highs On Monday

Financial news for CCXI dated on 2020-02-03: Shares of several healthcare companies are trading higher in sympathy with the overall market on a rebound after increased fear of the Wuhan coronavirus' impact on the economy dropped the Dow roughly 600 points on Friday.

Financial news for CCXI dated on 2020-01-27: 23 Biotechnology Stocks Moving In Monday's After-Market Session

Financial news for CCXI dated on 2020-01-27: 36 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for CCXI dated on 2020-01-24: 10 Biggest Price Target Changes For Friday

Financial news for CCXI dated on 2020-01-24: H.C. Wainwright Maintains Buy on ChemoCentryx, Raises Price Target to \$60

Financial news for CCXI dated on 2020-01-23: 146 Biotechnology Stocks Moving In Thursday's Session

Financial news for CCXI dated on 2020-01-23: ChemoCentryx shares are trading lower. Not currently seeing any company-specific news.

Financial news for CCXI dated on 2020-01-22: The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

Financial news for CCXI dated on 2020-01-21: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CCXI dated on 2020-01-17: Stocks That Hit 52-Week Highs On Friday

Financial news for CCXI dated on 2020-01-17: ChemoCentryx shares are trading higher on continued momentum after the company held its presentation at the JP Morgan Healthcare Conference on Tuesday.

Financial news for CCXI dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for CCXI dated on 2020-01-16: ChemoCentryx shares are trading higher following yesterday's presentation at the JP Morgan Healthcare Conference.

Financial news for CCXI dated on 2020-01-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for CCXI dated on 2020-01-03: The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

Financial news for CCXI dated on 2020-01-02: ChemoCentryx shares are trading lower. Not seeing any company-specific news to justify the price action.

Financial news for CCXI dated on 2020-01-02: The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe

Financial news for CCXI dated on 2019-12-30: ChemoCentryx shares are trading higher. Not seeing any news to justify the price action.

Financial news for CCXI dated on 2019-12-26: The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

Financial news for CCXI dated on 2019-12-16: ChemoCentryx shares are trading higher. Not currently seeing any company-specific news.

Financial news for CCXI dated on 2019-12-12: ChemoCentryx shares are trading higher

in sympathy with the overall market amid positive US-China trade developments which have caused US equities across many sectors to trade higher.

Financial news for CCXI dated on 2019-12-09: There's A Really Good Chance You Missed One Of The Year's Best ETFs

Financial news for CCXI dated on 2019-12-06: 75 Biggest Movers From Yesterday

Financial news for CCXI dated on 2019-12-05: ChemoCentryx shares are trading higher. Not currently seeing any company-specific news.

Financial news for CCXI dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for CCXI dated on 2019-11-27: The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen

Financial news for CCXI dated on 2019-11-27: 60 Biggest Movers From Yesterday

Financial news for CCXI dated on 2019-11-26: Mid-Afternoon Market Update: Dick's Sporting Goods Jumps On Earnings Beat; Dollar Tree Shares Plunge

Financial news for CCXI dated on 2019-11-26: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CCXI dated on 2019-11-26: Mid-Day Market Update: Movado Falls Following Downbeat Q3 Results; ChemoCentryx Shares Surge

Financial news for CCXI dated on 2019-11-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CCXI dated on 2019-11-26: ChemoCentryx Stock More Than Triples On Late-Stage Readout For Rare Inflammatory Disease Drug

Financial news for CCXI dated on 2019-11-26: Mid-Morning Market Update: Markets Edge Higher; Best Buy Profit Tops Expectations

Financial news for CCXI dated on 2019-11-26: Benzinga Pro's Top 5 Stocks To Watch For Tues., Nov. 26, 2019: BBY, CCXI, PANW, DLTR, DE

Financial news for CCXI dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for CCXI dated on 2019-11-26: 14 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for CCXI dated on 2019-11-26: 24 Stocks Moving in Tuesday's Pre-Market Session

Financial news for CCXI dated on 2019-11-26: Raymond James Maintains Strong Buy on ChemoCentryx, Raises Price Target to \$56

Financial news for CCXI dated on 2019-11-26: ChemoCentryx shares are trading higher after the company announced the pivotal phase-III ADVOCATE trial of avacopan for the treatment of patients with ANCA-associated vasculitis met both primary endpoints.

Financial news for CCXI dated on 2019-11-26: VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan's Superiority Over Standard of Care in ANCA Associated Vasculitis

Financial news for CCXI dated on 2019-11-25: ChemoCentryx To Resume Trade At 4:35 p.m. ET

Financial news for CCXI dated on 2019-11-25: ChemoCentryx Reports Topline Data From Pivotal Phase 3 ADVOCATE Trial Met Both Primary Endpoints

Financial news for CCXI dated on 2019-11-25: ChemoCentryx Shares Halted News Pending

Financial news for CCXI dated on 2019-11-19: ChemoCentryx Option Alert: Dec 20 \$10 Calls at the Ask: 3000 @ \$2.451 vs 4676 OI; Ref=\$8.745

Financial news for CCXI dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for CCXI dated on 2019-11-04: ChemoCentryx Q3 EPS \$(0.22) Beats \$(0.28) Estimate, Sales \$10.58M Beat \$7.7M Estimate

Financial news for CCXI dated on 2019-09-12: Benzinga's Top Upgrades, Downgrades For September 12, 2019

Financial news for CCXI dated on 2019-09-12: 10 Biggest Price Target Changes For Thursday

Financial news for CCXI dated on 2019-09-12: JP Morgan Upgrades ChemoCentryx to Overweight, Lowers Price Target to \$14

Financial news for CCXI dated on 2019-08-07: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

Financial news for CCXI dated on 2019-08-07: 85 Biggest Movers From Yesterday

Financial news for CCXI dated on 2019-08-06: 68 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CCXI dated on 2019-08-06: Stocks That Broke Yearly Lows Tuesday Morning

Financial news for CCXI dated on 2019-08-05: ChemoCentryx shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results.

Financial news for CCXI dated on 2019-08-05: ChemoCentryx Q2 EPS \$(0.26) Misses \$(0.22) Estimate, Sales \$7.173M Miss \$9.83M Estimate

Financial news for CCXI dated on 2019-08-05: New 52-Week Lows For Monday Morning

Financial news for CCXI dated on 2019-07-26: The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint

Financial news for CCXI dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for CCXI dated on 2019-06-06: 10 Biggest Price Target Changes For Thursday

Financial news for CCXI dated on 2019-06-06: Raymond James Maintains Strong Buy on ChemoCentryx, Lowers Price Target to \$17

Financial news for CCXI dated on 2019-06-06: The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

Financial news for CCXI dated on 2019-06-06: 66 Biggest Movers From Yesterday

Financial news for CCXI dated on 2019-06-05: InflaRx Shares Slammed As Skin Inflammation Drug Flunks Midstage Trial; ChemoCentryx Moves In Sympathy

Financial news for CCXI dated on 2019-06-05: 44 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CCXI dated on 2019-06-05: ChemoCentryx Shares Down 23% Wednesday Morning; JP Morgan Analyst Anupam Rama Tells Benzinga Stock Moving Given 'read-through from InflaRx trial set back'

Financial news for CCXI dated on 2019-06-05: ChemoCentryx shares are trading lower in sympathy with InflaRx (IFRX) after the latter company announced failed results from its C5a inhibitor study.

Financial news for CCXI dated on 2019-05-07: ChemoCentryx S-3 Shows Registration For \$200M Mixed Securities Offering

Financial news for CCXI dated on 2019-05-06: Chemocentryx Q1 EPS \$(0.23) Beats \$(0.24) Estimate, Sales \$8.33M Miss \$10.97M Estimate

Financial news for CCXI dated on 2019-04-02: ChemoCentryx To Present At H.C. Wainwright Global Life Sciences Conference

Financial news for CCXI dated on 2019-03-28: 71 Biggest Movers From Yesterday

Financial news for CCXI dated on 2019-03-27: 60 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CCXI dated on 2019-03-27: ChemoCentryx shares are trading higher after B. Riley FBR upgraded the company's stock from Neutral to Buy and raised its price target from \$12.50 to \$22 per share.

Financial news for CCXI dated on 2019-03-27: 10 Biggest Price Target Changes For Wednesday

Financial news for CCXI dated on 2019-03-27: Benzinga's Top Upgrades, Downgrades For March 27, 2019

Financial news for CCXI dated on 2019-03-27: B. Riley FBR Upgrades ChemoCentryx to Buy, Raises Price Target to \$22

Financial news for CCXI dated on 2019-03-26: On March 25, 2019, ChemoCentryx Sold ~4.82M Shares of Common Stock Pursuant to Equity Distribution Agreement with Piper Jaffray @11.40/Share

Financial news for CCXI dated on 2019-03-26: 52 Biggest Movers From Yesterday

Financial news for CCXI dated on 2019-03-25: ChemoCentryx shares traded higher, continuing momentum from Friday when the stock rose about 4 percent. Did not see news to justify the move higher.

Financial news for CCXI dated on 2019-02-11: Benzinga's Top Upgrades, Downgrades For February 11, 2019

Financial news for CCXI dated on 2019-02-11: PiperJaffray Initiates Coverage On ChemoCentryx with Overweight Rating, Announces \$20 Price Target

Financial news for CCXI dated on 2019-01-24: Chemocentryx Announces Withdrawal Of Phase II-based Conditional Marketing Authorization Application For Anca-Associated Vasculitis In Europe; Phase III Advocate Trial Data Release Planned For Q4 2019

Financial news for CCXI dated on 2018-12-04: ChemoCentryx Filing Shows Registration For \$75M Common Stock Offering

Financial news for CCXI dated on 2018-11-12: 85 Biggest Movers From Friday

Financial news for CCXI dated on 2018-11-08: Chemocentryx Q3 EPS \$(0.22) Beats \$(0.24) Estimate, Sales \$8.98M Miss \$11.89M Estimate

Financial news for CCXI dated on 2018-10-01: 46 Biggest Movers From Friday

Financial news for CCXI dated on 2018-09-28: Mid-Afternoon Market Update: Progress Software Falls Following Mixed Q3 Results; ChemoCentryx Shares Climb

Financial news for CCXI dated on 2018-09-28: 34 Stocks Moving In Friday's Mid-Day Session

Financial news for CCXI dated on 2018-09-28: Mid-Day Market Update: Crude Oil Up 1.5%; Altimmune Shares Plunge

Financial news for CCXI dated on 2018-09-28: ChemoCentryx shares are up 16.2% after the company earlier withdrew its plans for a public offering of common stock.

Financial news for CCXI dated on 2018-09-28: Mid-Morning Market Update: Markets Edge Lower; BlackBerry Earnings Beat Expectations

Financial news for CCXI dated on 2018-09-28: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for CCXI dated on 2018-09-28: 51 Biggest Movers From Yesterday

Financial news for CCXI dated on 2018-09-28: ChemoCentryx Withdraws Plans for Public Offering of Common Stock

Financial news for CCXI dated on 2018-09-27: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for CCXI dated on 2018-09-27: Mid-Morning Market Update: Markets Open Higher; Conagra Misses Q1 Views

Financial news for CCXI dated on 2018-09-27: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for CCXI dated on 2018-09-27: 10 Stocks To Watch For September 27, 2018

Financial news for CCXI dated on 2018-09-26: ChemoCentryx Reports \$75M Common Stock Offering

Financial news for CCXI dated on 2018-09-19: 60 Biggest Movers From Yesterday

Financial news for CCXI dated on 2018-09-18: Mid-Afternoon Market Update: Crude Oil Up 1.4%; Apogee Enterprises Shares Fall On Earnings Miss

Financial news for CCXI dated on 2018-09-18: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CCXI dated on 2018-09-18: Mid-Day Market Update: Dow Rises 125 Points; Twin Disc Shares Plummet

Financial news for CCXI dated on 2018-09-18: Vifor Pharma Group Earlier Reported Raised Equity Stake In ChemoCentryx From 6.6% To 21.2%

Financial news for CCXI dated on 2018-09-10: 52 Biggest Movers From Friday

Financial news for CCXI dated on 2018-09-07: B. Riley FBR Initiates Coverage On ChemoCentryx with Neutral Rating, Announces \$12.50 Price Target

Financial news for CCXI dated on 2018-08-15: 58 Biggest Movers From Yesterday

Financial news for CCXI dated on 2018-08-14: 45 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CCXI dated on 2018-08-14: ChemoCentryx Inc. shares are trading 8.4% lower to \$11.59 after JP Morgan downgraded the company to a "Neutral" rating.

Financial news for CCXI dated on 2018-08-14: JP Morgan Downgrades ChemoCentryx to Neutral, Raises Price Target to \$15

Financial news for CCXI dated on 2018-08-09: Chemocentryx Q2 EPS \$(0.14) Beats \$(0.15) Estimate, Sales \$15.022M Beat \$14.06M Estimate

Financial news for CCXI dated on 2018-06-28: Raymond James Initiates Coverage On ChemoCentryx with Strong Buy Rating, Announces \$18 Price Target

Financial news for CCXI dated on 2018-06-07: UPDATE: ChemoCentryx Says Vifor To Pay Co. \$10M Related To Expansion Of Collaboration, License Deal To Include China

Financial news for CCXI dated on 2018-06-07: UPDATE: ChemoCentryx, Vifor Entered Amendment To Collaboration, License Deal To Account For Exclusive License To Commercialize CCX140 In Certain Countries Outside US, Vifor To Pay ~\$11.5M

Financial news for CCXI dated on 2018-06-07: ChemoCentryx 8-K Shows Co., Vifor Fresenius Medical Care Renal Pharma Expanded Global Commercial Alliance To Provide Vifor With Commercialization Rights In China In Exchange For Upfront Cash Payments Of \$21.5M

Financial news for CCXI dated on 2018-06-04: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for CCXI dated on 2018-05-17: 41 Biggest Movers From Yesterday

Financial news for CCXI dated on 2018-05-16: ChemoCentryx Shares Up 7.5% After Canaccord Genuity Earlier Initiated Coverage On Stock With Buy Rating And \$17 Price Target

Financial news for CCXI dated on 2018-05-16: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CCXI dated on 2018-05-16: Benzinga's Top Upgrades, Downgrades For May 16, 2018

Financial news for CCXI dated on 2018-05-16: Canaccord Genuity Initiates Coverage On ChemoCentryx with Buy Rating, Announces \$17 Price Target

Financial news for CCXI dated on 2018-05-09: Chemocentryx Q1 EPS \$(0.19) Beats \$(0.25) Estimate, Sales \$9.55M Beat \$6.3M Estimate

Financial news for CCXI dated on 2018-05-02: Benzinga's Top Upgrades, Downgrades For May 2, 2018

Financial news for CCXI dated on 2018-05-02: H.C. Wainwright Initiates Coverage On ChemoCentryx with Buy Rating, Announces \$20 Price Target

Financial news for CCXI dated on 2018-03-12: 44 Biggest Movers From Friday

Financial news for CCXI dated on 2018-03-09: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for CCXI dated on 2018-03-09: ChemoCentryx Shares Up 10.4% After Q4 Results

Financial news for CCXI dated on 2018-03-09: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for CCXI dated on 2018-03-09: ChemoCentryx Reports Q4 EPS \$0.80 vs \$(0.16) In Same Qtr. Last Year, Sales \$56.301M vs \$4.889M YoY

Financial news for CCXI dated on 2018-03-09: Earnings Scheduled For March 9, 2018

Financial news for CCXI dated on 2018-01-22: UPDATE: ChemoCentryx Says 'Clinical findings to be presented at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium'

Financial news for CCXI dated on 2018-01-22: ChemoCentryx Reports Overall Survival Results With CCX872 For Locally Advanced/Metastatic Pancreatic Cancer: 'CCX872 plus FOLFIRINOX resulted in overall survival of 29 percent at 18 months in all patients'

Financial news for CCXI dated on 2018-01-08: ChemoCentryx Earlier Announced Co. Has Named William Fairey COO

Financial news for CCXI dated on 2018-01-05: 36 Biggest Movers From Yesterday

Financial news for CCXI dated on 2018-01-04: Mid-Afternoon Market Update: Dow Rises Over 150 Points; L Brands Shares Plunge

Financial news for CCXI dated on 2018-01-04: Mid-Day Market Update: Buckle Drops After December Sales Results; ChemoCentryx Shares Spike Higher

Financial news for CCXI dated on 2018-01-04: 33 Stocks Moving In Thursday's Mid-Day Session

Financial news for CCXI dated on 2018-01-04: Mid-Morning Market Update: Markets Open Higher; Walgreens Earnings Top Views

Financial news for CCXI dated on 2018-01-04: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for CCXI dated on 2018-01-04: UPDATE: ChemoCentryx Entered \$50M 'Growth Capital Financing Agreement with Hercules Capital'

Financial news for CCXI dated on 2018-01-04: UPDATE: ChemoCentryx Says Will 'Receive \$50M Milestone from Vifor Pharma for Validation of Conditional Marketing Authorization Application for Avacopan for the Treatment of ANCA Vasculitis'

Financial news for CCXI dated on 2018-01-04: ChemoCentryx Reports Securing Of Up To \$100M In New Capital Commitments

Financial news for CCXI dated on 2018-01-04: ChemoCentryx Announces EMA has Accepted for Review the Registration Dossier in Support of Conditional Marketing Authorization for Avacopan in the Treatment of Patients with ANCA-Associated Vasculitis

Financial news for CCXI dated on 2017-11-07: ChemoCentryx Reports Q3 EPS \$(0.13) vs \$(0.15) In Same Qtr. Last Year, Sales \$9.029M vs \$9.03M Est.

Financial news for CCXI dated on 2017-09-01: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for CCXI dated on 2017-08-08: ChemoCentryx Reports Q2 Loss/Share \$(0.19) vs. \$(0.17) Est., Sales \$8.9M vs. \$8.5M Est.

Financial news for CCXI dated on 2017-06-28: ChemoCentryx Receives EU Orphan Designation For Avacopan

Financial news for CCXI dated on 2017-06-06: UPDATE: ChemoCentryx Says 'Clinical Study Shows Drop in Proteinuria in Patients Treated with Avacopan for IgAN

Financial news for CCXI dated on 2017-06-06: ChemoCentryx Reports Oral Presentations at ERA-EDTA Congress Showed Fourth Potential Indication for Avacopan, Potential for CCR2 Inhibition in FSGS

Financial news for CCXI dated on 2017-05-23: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy

Financial news for CCXI dated on 2017-05-10: ChemoCentryx Reports Q1 EPS \$(0.12) vs \$(0.26) Est., Sales \$8.23M vs \$5.3M Est.

Financial news for CCXI dated on 2017-03-22: ChemoCentryx Reports Received FDA Orphan Drug Designation for Avacopan for Treatment of C3G

Financial news for CCXI dated on 2017-03-14: ChemoCentryx Reports Q4 EPS \$(0.16) vs

\$(0.22) Est., Sales \$4.889M vs \$3.3M Est.

Financial news for CCXI dated on 2017-02-14: UPDATE: ChemoCentryx Will Receive Added \$20M Upfront Cash Commitment Plus Royalties on Potential Net Sales

Financial news for CCXI dated on 2017-02-14: Galenica's Vifor Pharma, ChemoCentryx Report Expansion of Avacopan Deal for Rare Renal Diseases

Financial news for CCXI dated on 2017-01-20: ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer

Financial news for CCXI dated on 2016-12-22: ChemoCentryx Expands Partnership With Vifor Pharma, Licenses CCX140 For Renal Diseases

Financial news for CCXI dated on 2016-12-22: ChemoCentryx Shares Resume Trade, Turn Positive, Now Up 9%

Financial news for CCXI dated on 2016-12-22: ChemoCentryx Shares to Resume Trade at 1 p.m. EST

Financial news for CCXI dated on 2016-12-22: Vifor Pharma, ChemoCentryx Announces Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases, Will Receive Upfront \$50M Cash Commitment Plus Possible Milestones, Royalties

Financial news for CCXI dated on 2016-12-22: ChemoCentryx Shares Halted News Pending

Financial news for CCXI dated on 2016-11-17: American Society Of Nephrology (ASN) Kidney Week Taking Place In Chicago

Financial news for CCXI dated on 2016-11-09: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CCXI dated on 2016-11-07: ChemoCentryx Reports Q3 EPS \$(0.15) vs. Est. \$(0.08), Rev. \$4.25M vs. Est. \$1.2M

Financial news for CCXI dated on 2016-10-18: ChemoCentryx Reports CCX872 Shown to Reduce Liver Fibrosis in NASH Models

Financial news for CCXI dated on 2016-10-17: ChemoCentryx Reports Data from Ongoing Pilot Phase II Trial of CCX168 in aHUS: 'Treatment of aHUS patients with CCX168 effective in reducing aHUS serum-induced thrombus formation'

Financial news for CCXI dated on 2016-09-29: 15 Stocks That Rallied 4 Days, Then Sold Off Yesterday

Financial news for CCXI dated on 2016-09-27: ChemoCentryx Shares Up 9.87% On Mid-Morning Trading

Financial news for CCXI dated on 2016-09-02: Mid-Afternoon Market Update: Accuride Jumps Following Acquisition Announcement; Lululemon Shares Slide

Financial news for CCXI dated on 2016-09-02: 10 Biggest Mid-Day Losers For Friday

Financial news for CCXI dated on 2016-09-02: Mid-Day Market Update: Crude Oil Up 3%; VeriFone Shares Decline On Lowered Forecast

Financial news for CCXI dated on 2016-09-02: Mid-Morning Market Update: Markets Open Higher; Lululemon Sales Miss Views

Financial news for CCXI dated on 2016-09-01: ChemoCentryx Reports Initial Results from Ongoing Phase Ib Clinical Trial of CCX872 in Patients with Advanced Pancreatic Cancer

Financial news for CCXI dated on 2016-08-08: After-Hours Gainers Aug. 8, 2016: HIIQ Up 36%, REN 20%, CCXI 14.4%, FH 14.3%, FGEN 10.4%, AMPH 9.4%, CSLT 8.9%, NVRO 8.7%, ENDP 7.5%

Financial news for CCXI dated on 2016-08-08: ChemoCentryx Reports Q2 EPS \$(0.22) vs. Est. \$0.07, Rev. \$2.7M Does Not Compare To \$19.2M

Financial news for CCXI dated on 2016-06-16: ChemoCentryx Reports Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development

Financial news for CCXI dated on 2016-06-01: ChemoCentryx Reports Received EMA PRIME Designation for Accelerated Assessment of CCX168 for Treatment of Patients with ANCA-Associated Vasculitis

Financial news for CCXI dated on 2016-05-23: ChemoCentryx Reports Phase II Clear Trial Met Primary Endpoint

Financial news for CCXI dated on 2016-05-18: Midday Gainers In Depth

Financial news for CCXI dated on 2016-05-17: Director Edwards Buys 25,000 Shares of ChemoCentryx @\$4.05/Share -Form 4

Financial news for CCXI dated on 2016-05-16: ChemoCentryx Spikes to High of \$4.29 on Vol; Insider Buy of 40K Shares Reported Late Fri

Financial news for CCXI dated on 2016-05-13: Dir Parker Buys 40,000 Shares of ChemoCentryx @\$4.03/Share -Form 4

Financial news for CCXI dated on 2016-05-11: ChemoCentryx Inc Shares Up 50.50% On The Day At \$4.46/Share

Financial news for CCXI dated on 2016-05-10: Mid-Afternoon Market Update: Dow Jumps Over 200 Points; SolarCity Shares Tumble

Financial news for CCXI dated on 2016-05-10: Mid-Day Market Update: Sodastream Gains Following Earnings Beat; NewLink Genetics Shares Decline

Financial news for CCXI dated on 2016-05-10: Mid-Morning Market Update: Markets Open Higher; Allergan Earnings Top Views

Financial news for CCXI dated on 2016-05-10: 12 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CCXI dated on 2016-05-10: UPDATE: ChemoCentryx Now +109% Premarket @\$4.40 Following US Press Release Announcing Licence Agreement for CCX168

Financial news for CCXI dated on 2016-05-10: ChemoCentryx Reports Q1 Loss \$15.2M, EPS \$(0.34) vs \$(0.27) Est.

Financial news for CCXI dated on 2016-05-10: ChemoCentryx +90% Premarket @\$4.00 Following Announcement of Licence Agreement for CCX168

Financial news for CCXI dated on 2016-05-10: Vifor Pharma Licenses Marketing Rights to ChemoCentryx's CCX168 in Europe, Canada, Mexico, Central and S. America, S. Korea; ChemoCentryx to Receive Upfront Payment of \$60M, Equity Investment of \$25M @\$7.50/Share

Financial news for CCXI dated on 2016-04-28: ChemoCentryx Reports Received FDA Orphan Products Development Grant for Orally-Administered Complement CCX168 for Treatment of ANCA-Associated Vasculitits

Financial news for CCXI dated on 2016-04-13: Chemocentryx Files For Mix Shelf Up To \$150M

Financial news for CCXI dated on 2016-03-14: ChemoCentryx Reports Q4 Earnings \$(11.6M) vs \$(12.2M) in Same Qtr. Last Year

Financial news for CCXI dated on 2016-01-06: UPDATE: ChemoCentryx Says Primary Endpoint Achieved, CCX168 Appears Safe, Well Tolerated

Financial news for CCXI dated on 2016-01-06: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168

Financial news for CCXI dated on 2015-11-09: Chemocentryx Reports Q3 EPS \$(0.26) vs \$(0.29) Est.

Financial news for CCXI dated on 2015-11-04: ChemoCentryx Announces Immuno-Oncology Data Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Financial news for CCXI dated on 2015-09-24: Wednesday's After-Hours Movers: 10 Stocks To Watch

Financial news for CCXI dated on 2015-08-06: ChemoCentryx Reports Q2 Loss \$0.28 Vs Est Loss \$0.29

Financial news for CCXI dated on 2015-05-29: Encouraging Results From ChemoCentryx Phase II Diabetic Nephropathy Trial With Chemokine Receptor CCR2 Inhibitor CCX140 Highlighted at the 52nd ERA-EDTA Congress

Financial news for CCXI dated on 2015-05-26: Positive Clinical Data From ChemoCentryx Phase II Trial in Diabetic Nephropathy to be Showcased at the 52nd Annual ERA-EDTA

Congress

Financial news for CCXI dated on 2015-05-18: JP Morgan Upgrades Chemocentryx to Overweight, Raises PT to \$14.00

Financial news for CCXI dated on 2015-05-06: Chemocentryx Reports Q1 Loss of \$0.28/Share, Inline

Financial news for CCXI dated on 2015-04-20: ChemoCentryx Begins Clinical Trial of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, in Pancreatic Cancer

Financial news for CCXI dated on 2015-03-12: ChemoCenryx Reports Inline Q4 EPS -\$0.28

Financial news for CCXI dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Financial news for CCXI dated on 2014-12-12: Biggest Gainers From Friday, December 12, 2014

Financial news for CCXI dated on 2014-12-12: Mid-Morning Market Update: Markets Open Lower; Adobe Earnings Top Expectations

Financial news for CCXI dated on 2014-12-12: 2 Stocks With Trending Social Sentiment Today

Financial news for CCXI dated on 2014-12-12: ChemoCentryx Up 70%, Lead Drug Meets Phase II Objective

Financial news for CCXI dated on 2014-12-12: Morning Market Movers

Financial news for CCXI dated on 2014-12-12: Benzinga's Top #PreMarket Gainers

Financial news for CCXI dated on 2014-12-12: ChemoCentryx Shares Rise 100% Premarket as Primary Endpoint Achieved in Phase II CCX140 Trial

Financial news for CCXI dated on 2014-12-12: ChemoCentryx Reports Positive Phase II Diabetic

Financial news for CCXI dated on 2014-12-12: ChemoCentryx Announces Primary Endpoint Achieved in Phase II CCX140 Trial

Financial news for CCXI dated on 2014-12-04: ChemoCentryx Granted EU Orphan Drug Designation For CCX168

Financial news for CCXI dated on 2014-11-20: ChemoCentryx Inc's CCX168 Granted Orphan-Drug Designation

Financial news for CCXI dated on 2014-11-05: ChemoCentryx, Inc. Reports Q3 EPS of \$(0.25) vs \$(0.28) Est

Financial news for CCXI dated on 2014-10-21: ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown to be Well Tolerated and Effective in CCR9 Blockade in Phase I Study

Financial news for CCXI dated on 2014-10-21: ChemoCentryx's CCR9 Inhibitor Shown to Be Well Tolerated for Treatment of Inflammatory Bowel Diseases

Financial news for CCXI dated on 2014-10-20: ChemoCentryx Releases Phase III SHIELD 4 Clinical Results In Patients With Crohn's Disease

Financial news for CCXI dated on 2014-09-30: Option Alert: Chemocentryx Shares Spike Higher; 1,000 Feb \$5 Calls Traded at Ask @\$1.10; Currently \$4.76

Financial news for CCXI dated on 2014-06-03: ChemoCentryx's CCX168 Granted FDA Orphan-Drug Designation in ANCA-Associated Diseases

Financial news for CCXI dated on 2014-06-02: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements

Financial news for CCXI dated on 2014-05-08: ChemoCentryx, Inc. Reports Q1 EPS of \$(0.27)

Financial news for CCXI dated on 2014-03-27: ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology

Financial news for CCXI dated on 2013-12-04: Benzinga's Top #PreMarket Gainers

Financial news for CCXI dated on 2013-12-04: Citigroup Downgrades ChemoCentryx, Inc.

to Neutral

Financial news for CCXI dated on 2013-12-03: ChemoCentryx Reports Positive Top-Line Results of CCX168 Phase I Data, Shows Appears to Be Safe

Financial news for CCXI dated on 2013-11-07: ChemoCentryx, Inc. Reports Q3 EPS of \$(0.22) vs \$(0.26) Est; Revenue of \$1.52M vs \$1.97M Est

Financial news for CCXI dated on 2013-09-18: ChemoCentryx Will Regain Global Rights for Vercirnon from Glaxo, Will Assess If Drug Maintains Remission in Crohn's Disease

Financial news for CCXI dated on 2013-09-17: GlaxoSmithKline Terminates Crohn's Drug Program Following ChemoCentryx Trial Failure -FierceBiotech

Financial news for CCXI dated on 2013-09-10: JP Morgan Downgrades ChemoCentryx, Inc. to Neutral

Financial news for CCXI dated on 2013-09-10: Morning Market Losers

Financial news for CCXI dated on 2013-09-10: Benzinga's Top Pre-Market Losers

Financial news for CCXI dated on 2013-09-10: US Stock Futures Up After Upbeat China Data

Financial news for CCXI dated on 2013-09-10: ChemoCentryx Issues Top-Line Interim Results for CCX140, Says Data Showed Statistically Significant Reduction in Protein

Financial news for CCXI dated on 2013-08-23: Shares of ChemoCentryx Resume Trade, Now Down 40+%

Financial news for CCXI dated on 2013-08-23: Shares of ChemoCentryx Halted on LULD Trading Pause, Stock is Down 30.7%

Financial news for CCXI dated on 2013-08-23: Shares of ChemoCentryx Resume Trade, Down 28%

Financial news for CCXI dated on 2013-08-23: ChemoCentryx Shares to Resume Trade at 9:55AM EDT

Financial news for CCXI dated on 2013-08-23: ChemoCentryx Says Glaxo's Top-Line Results from SHIELD-1 Phase III Study of Vercirnon Did Not Meet Primary Endpoint

Financial news for CCXI dated on 2013-08-23: ChemoCentryx Shares Halted News Pending

Financial news for CCXI dated on 2013-08-12: ChemoCentryx, Inc. Reports Q2 EPS of \$(0.23) vs \$(0.28) Est

Financial news for CCXI dated on 2013-05-28: ChemoCentryx Announces Appointment of Health Care Insurance Executive Ira Klein, MD, to Company's Board of Directors

Financial news for CCXI dated on 2013-05-20: UPDATE: Stifel Nicolaus Raises PT on ChemoCentryx Following R&D Day

Financial news for CCXI dated on 2013-05-20: Stifel Nicolaus Maintains Buy on ChemoCentryx, Inc., Raises PT to \$20.00

Financial news for CCXI dated on 2013-05-17: J.P. Morgan Reiterates Neutral Rating on ChemoCentryx Following Analyst Day

Financial news for CCXI dated on 2013-05-13: ChemoCentryx, Inc. Reports Q1 EPS of \$(0.28) vs \$(0.27) Est

Financial news for CCXI dated on 2013-05-13: Earnings Scheduled For May 13, 2013

Financial news for CCXI dated on 2013-04-22: ChemoCentryx Closes Follow-On Offering of 5M Shares at \$12/Share

Financial news for CCXI dated on 2013-04-17: ChemoCentryx Prices 5M Share Offering at \$12.00/Share

Financial news for CCXI dated on 2013-03-20: ChemoCentryx Files \$150M Mixed Securities Shelf

Financial news for CCXI dated on 2013-03-20: ChemoCentryx Files \$150M Mixed Securities Shelf

Financial news for CCXI dated on 2013-03-13: ChemoCentryx, Inc. Reports Q4 EPS of \$(0.28), Inline

Financial news for CCXI dated on 2013-03-13: Earnings Scheduled For March 13, 2013

Financial news for CCXI dated on 2013-01-07: ChemoCentryx Announces Initiation of Phase I Clinical Trial for CCX507

Financial news for CCXI dated on 2012-11-14: UPDATE: Stifel Nicolaus Initiates Buy on ChemoCentryx on Potential of Lead Drug Candidate

Financial news for CCXI dated on 2012-11-14: Stifel Nicolaus Initiates Coverage on Chemocentryx at Buy, Announces PT of \$16

Financial news for CCXI dated on 2012-10-02: From Earlier: ChemoCentryx Reports Data for CCX872

Financial news for CCXI dated on 2012-06-08: ChemoCentryx Announces Peer-Reviewed Publication of Positive Phase 2 Clinical Data with CCX354, a Novel Inhibitor of Chemokine Receptor CCR1 in Patients with Rheumatoid Arthritis

Financial news for CCXI dated on 2012-05-10: ChemoCentryx Reports Q1 EPS \$(0.28) vs \$(0.21) Est

Financial news for CCXI dated on 2012-03-19: JP Morgan Initiates Coverage on Chemocentryx at Overweight, Announces PT of \$16

Financial news for CCXI dated on 2012-02-08: ChemoCentryx IPO Opens for Trading at \$10.32, after Originally Pricing at \$10.00/Share

Financial news for CCXI dated on 2012-02-08: ChemoCentryx Prices Initial Public Offering of 4.5M Shares at \$10